We identify the DNA-damage sensor kinase ATR as a MYB downstream therapeutic target that is overexpressed in ACC and show that treatment with a phase 2 ATR kinase inhibitor induce apoptosis in MYB-positive ACC cells and growth inhibition in ACC patient-derived xenografts (PDXs). Here, ATR is linked to adrenal cortex carcinoma.